← Back to Search

HP 129Xe MRI for Lung Transplant Rejection

Phase 2
Recruiting
Led By Giles Santyr, PhD
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial uses MRI to study how well lungs work after a transplant.

Who is the study for?
This trial is for stable adult lung transplant recipients at UHN Toronto Lung Transplant Program. It includes those diagnosed with CLAD and those without it after a year of follow-up, provided they have an FEV1 over 1.0 L and are double lung transplant recipients. Exclusions apply to pregnant women, individuals unable to travel for MRI scans, or with conditions that prevent MRI use.
What is being tested?
The study tests the use of hyperpolarized 129Xe MRI in detecting changes in the lungs of patients who have received transplants. The goal is to see if this imaging method can effectively identify structural and functional changes associated with lung transplant rejection (CLAD).
What are the potential side effects?
Since the intervention involves only an imaging procedure using hyperpolarized xenon gas during an MRI scan, side effects may be minimal but could include discomfort from lying still during the scan or mild anxiety due to claustrophobia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
129Xe-MRI
Secondary study objectives
1H-MRI

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
Participants will inhale hyperpolarized 129Xe gas.

Find a Location

Who is running the clinical trial?

University Health Network, TorontoOTHER
1,531 Previous Clinical Trials
504,307 Total Patients Enrolled
The Hospital for Sick ChildrenLead Sponsor
712 Previous Clinical Trials
6,959,784 Total Patients Enrolled
Giles Santyr, PhDPrincipal InvestigatorThe Hospital for Sick Children
6 Previous Clinical Trials
272 Total Patients Enrolled

Media Library

129Xenon Clinical Trial Eligibility Overview. Trial Name: NCT05550662 — Phase 2
Lung Transplant Rejection Research Study Groups: Single arm
Lung Transplant Rejection Clinical Trial 2023: 129Xenon Highlights & Side Effects. Trial Name: NCT05550662 — Phase 2
129Xenon 2023 Treatment Timeline for Medical Study. Trial Name: NCT05550662 — Phase 2
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top